Literature DB >> 26235238

Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer.

N Hirahara1, T Matsubara2, H Hayashi2, K Takai2, Y Fujii2, Y Tajima2.   

Abstract

BACKGROUND: Despite recent improvements in early detection, progress in surgical techniques, and development of chemoradiation therapies, prognosis of esophageal cancer remains poor. The aim of the present study was to assess whether Glasgow Prognostic Score (GPS), an inflammation-based prognostic score, has prognostic value independent of conventional clinicopathological criteria in patients undergoing curative resection for esophageal cancer, even in elderly patients.
METHODS: We retrospectively reviewed the database of 141 consecutive patients with histologically verified esophageal squamous cell carcinoma who underwent potentially curative surgery in our institute, between January 2006 and December 2014. GPS and neutrophil lymphocyte ratio (NLR) were calculated.
RESULTS: On multivariate analysis, TNM stage (p < 0.0001) and GPS (p = 0.041) were independently associated with worse prognosis in overall patients with esophageal cancer. Multivariate analysis evaluated the prognostic factors in two different patient groups: patients younger than 70 years (non-elderly) and those aged 70 years or more (elderly). Multivariate analysis demonstrated that TNM stage (p = 0.0003) was an only independent risk factor for a worse prognosis among non-elderly group. Meanwhile, multivariate analysis demonstrated that TNM stage (p = 0.001) and GPS (p = 0.043) were the independent risk factor for a worse prognosis among elderly group.
CONCLUSION: The present study demonstrated that GPS is associated with prognosis and can be considered as an independent prognostic marker in patients who underwent esophagectomy. Moreover, the GPS has the advantage of being simple to measure, routinely available and well standardized. But the present study failed to confirm the NLR as a significant predictor of survival following resection for esophageal cancer.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; Glasgow Prognostic Score; Neutrophil lymphocyte ratio; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26235238     DOI: 10.1016/j.ejso.2015.07.008

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  25 in total

1.  Cancer Recurrence After Esophagectomy: Impact of Postoperative Infection in Propensity-Matched Cohorts.

Authors:  Vernissia Tam; James D Luketich; Daniel G Winger; Inderpal S Sarkaria; Ryan M Levy; Neil A Christie; Omar Awais; Manisha R Shende; Katie S Nason
Journal:  Ann Thorac Surg       Date:  2016-06-25       Impact factor: 4.330

2.  Evaluation of prognostic markers for patients with curatively resected thoracic esophageal squamous cell carcinomas.

Authors:  Masahide Ikeguchi; Yusuke Kouno; Kyoichi Kihara; Kazunori Suzuki; Kanenori Endo; Seiichi Nakamura; Takashi Sawada; Tetsu Shimizu; Tomoyuki Matsunaga; Yoji Fukumoto; Hiroaki Saito
Journal:  Mol Clin Oncol       Date:  2016-11-02

3.  Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.

Authors:  Naoya Yoshida; Yoshifumi Baba; Hironobu Shigaki; Kazuto Harada; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Junji Kurashige; Keisuke Kosumi; Ryuma Tokunaga; Masayuki Watanabe; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2016-06-02       Impact factor: 3.402

4.  Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma.

Authors:  Noriyuki Hirahara; Takeshi Matsubara; Daisuke Kawahara; Yoko Mizota; Shuichi Ishibashi; Yoshitsugu Tajima
Journal:  Int J Clin Oncol       Date:  2016-05-06       Impact factor: 3.402

5.  The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study.

Authors:  Takahiro Toyokawa; Naoshi Kubo; Tatsuro Tamura; Katsunobu Sakurai; Ryosuke Amano; Hiroaki Tanaka; Kazuya Muguruma; Masakazu Yashiro; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Cancer       Date:  2016-09-06       Impact factor: 4.430

6.  Validation of a novel prognostic scoring system using inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma.

Authors:  Noriyuki Hirahara; Yusuke Fujii; Tetsu Yamamoto; Ryoji Hyakudomi; Takanori Hirayama; Takahito Taniura; Kazunari Ishitobi; Yoshitsugu Tajima
Journal:  Onco Targets Ther       Date:  2017-01-13       Impact factor: 4.147

7.  Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis.

Authors:  Kazuki Kano; Toru Aoyama; Tetsushi Nakajima; Yukio Maezawa; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Takashi Oshima; Yasushi Rino; Munetaka Masuda; Haruhiko Cho; Takaki Yoshikawa; Takashi Ogata
Journal:  BMC Cancer       Date:  2017-12-04       Impact factor: 4.430

8.  C-reactive protein/albumin ratio predicts survival after curative surgery in elderly patients with colorectal cancer.

Authors:  Koki Tamai; Shu Okamura; Shunichiro Makino; Noriyuki Yamamura; Nariaki Fukuchi; Chikara Ebisui; Akira Inoue; Masahiko Yano
Journal:  Updates Surg       Date:  2021-03-06

9.  Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy.

Authors:  Noriyuki Hirahara; Takeshi Matsubara; Yoko Mizota; Shuichi Ishibashi; Yoshitsugu Tajima
Journal:  BMC Surg       Date:  2016-09-20       Impact factor: 2.102

10.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.

Authors:  Ross D Dolan; Jason Lim; Stephen T McSorley; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.